Pombiliti (cipaglucosidase alfa-atga) Coverage for Late-Onset Pompe Disease
Customize your policy alerts
Sign up for Molina Healthcare Policy C27242-A alerts
Get alerted when Policy C27242-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and prior authorization for intravenous Pombiliti used with Opfolda to treat adults with late-onset Pompe disease who weigh at least 40 kg and are not improving on current enzyme replacement therapy.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.